Age-related characteristics of the efficacy of different glucocorticosteroids in the therapy of acute lymphoblastic leukemia


Cite item

Full Text

Abstract

Aim. To determine predictors for decision-making on a differential approach to choosing glucocorticosteroids (GCS) for children and adolescents with acute lymphoblastic leukemia (ALL). Subjects and methods. The analysis covered 1064 primary patients aged to 1 to 18 years with ALL who had been registered at the clinics of Russia and Belorussia in April 2002 to November 2006. Before induction therapy, the patients were randomized into a dexamethasone (DEXA) 6 mg/m2 group (n=539) and a methylprednisolone (MePRED) 60 mg/m2 one (n=525). Results. The entire group showed no statistically significant differences in survival rates between the patients receiving DEXA or MePRED. However, an analysis of age groups revealed the benefits of DEXA in children younger than 14 years (the event-free survival (EFS) was 76±2 and 71±2%, respectively (p=0.048); the overall survival (OS) was 81±2 and 77±2%, respectively (р=0.046); therapy-induced mortality was 6.4% (DEXA) and11.1% (MePRED) (р=0.014); the rate of isolated extramedullary relapses was 1.5% (DEXA) and 4.4% (MePRED) ( р=0.009). At the same time, EFS and OS in 14-to-18-year-old adolescents were statistically significantly higher than in those who used MePRED (EFS, 65±6 and 52±6%, respectively (р=0.087); OS, 72±6 and 61±6%, respectively; (р=0.17). Conclusion. The findings suggest that it is possible that the choice of a GCS for ALL therapy must be also based on a patient’s age. There is a need for further studies of this matter in prospective randomized multicenter trials in children and adolescents.

References

  1. Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, Bajdun L, Maschan A, Fechina L, Shamardina A, Dudkin S, Lebedev V, Varfolomeeva S, Timofeeva V, Roumiantseva J, Chipsanova N, Rumjanzew A, Henze G: Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia. 2008;22: 1144-1153.
  2. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010;95:1489-1495.
  3. Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K: Risk group assignment differs for children and adults 1—45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol. 2013;90:404-412.
  4. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab. 1975;40:1073-1077.
  5. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9: 1783-1786.
  6. Machin D, Gardner MJ. Calculating confidence intervals for survival time analyses. Br Med J. (Clin Res Ed). 1988;296:1369-1371.
  7. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308:2594-2604.
  8. Foody G. Classification accuracy comparison: Hypothesis tests and the use of confidence intervals in evaluations of difference, equivalence and non-inferiority. Remote Sensing of Enviroment. 2009;113:1658-1663.
  9. Song JX. Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints. Computational Statistics & Data Analysis. 2009;53:1201-1207.
  10. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, Shah PS, Beyene J, Sung L. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25: 1232-1238.
  11. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11:1096-1106.
  12. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, Kamijo T, Isoyama K, Kajiwara M, Sotomatsu M, Sugita K, Sugita K, Maeda M, Yabe H, Kinoshita A, Kaneko T, Hayashi Y, Ikuta K, Hanada R, Tsuchida M. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95—14 protocol. J Clin Oncol. 2005;23:6489-6498.
  13. McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol. 2010;149:638-652.
  14. Bertrand Y, Suciu S, Benoit Y, Robert A, Nelken B, Uyttebroeck A, Lutz P, Ferster A, Baruchel A, Norton L, Margueritte G, Rohrlich P-S, Munzer M, Plantaz D, Millot F, Boutard P, Sirvent N, Hoyoux C, Baila L, Otten J: Dexamethasone (DEX) (6 mg/sm/d) and Prednisolone (PRED) (60 mg/sm/d) in Induction Therapy of Childhood ALL Are Equally Effective: Results of the 2nd Interim Analysis of EORTC Trial 58951. ASH Annual Meeting Abstracts. 2008;112:8.
  15. Schrappe M, Zimmermann M, Möricke A, Mann G, Valsecchi MG, Bartram CR, Biondi A, Panzer-Grümayer R, Schrauder A, Locatelli F, Reiter A, Basso G, Niggli F, Aricò M, Conter V: Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000). ASH Annual Meeting Abstracts. 2008;112:7.
  16. Kaspers GJ, Veerman AJ, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LM, Van Wering ER, Pieters R. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:114-121.
  17. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
  18. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Maurer HM, Koch K. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19:269-275.
  19. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME; Children’s Cancer Group. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 2003;101:3809-3817.
  20. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19:1040-1046.
  21. Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bähr V. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab. 2002; 87:5695-5701.
  22. Sai S, Nakagawa Y, Sakaguchi K, Okada S, Takahashi H, Hongo T, Seckl JR, Chapman KE, Ohzeki T. Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia. Leuk Res. 2009;33:1696-1698.
  23. Sai S, Nakagawa Y, Yamaguchi R, Suzuki M, Sakaguchi K, Okada S, Seckl JR, Ohzeki T, Chapman KE. Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells. Leuk Res. 2011;35: 1644-1648.
  24. Tao Y, Shi JM, Zhang YX, Gao L, Zhan FH. Expression of 11beta-hydroxysteroid dehydrogenase type 2 in lymphoblastic cells and its relationship with glucocorticoid sensitivity. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19:109-113.
  25. Garbrecht MR, Schmidt TJ. Expression and Regulation of 11- beta Hydroxysteroid Dehydrogenase Type 2 Enzyme Activity in the Glucocorticoid-Sensitive CEM-C7 Human Leukemic Cell Line. ISRNOncol. 2013;2013:245-246.
  26. Seckl JR. 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action? FrontNeuroendocrinol. 1997;18:49-99.
  27. Holmes MC, Sangra M, French KL, Whittle IR, Paterson J, Mullins JJ, Seckl JR. 11beta-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience. 2006;137:865-873.
  28. Holmes MC, Seckl JR. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol. 2006;248:9-14.
  29. Wyrwoll CS, Holmes MC, Seckl JR. 11beta-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol. 2011;32:265-286.
  30. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, Gelber RD, Sallan SE. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88:1964-1969.
  31. Eipel OT, Németh K, Török D, Csordás K, Hegyi M, Ponyi A, Ferenczy A, Erdélyi DJ, Csóka M, Kovács GT. The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy. Int J Hematol. 2013;97:216-222.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies